IDEXX Laboratories, Inc. (IDXX) delivered better-than-expected Q3 2021 results that affirm the impact of ongoing investments in innovation and global commercial capability.
Idexx Laboratories Inc.’s (IDXX) subsidiary Opti Medical Systems, Inc.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the fourth quarter of 2015 of $400 million, an increase of 14%1 compared to …
As widely expected, the new year has begun with a lot of volatility on high trading volume, as investors fear more than just …
Canaccord Genuity analyst Mark Massaro yesterday upgraded shares of Idexx Laboratories (IDXX) from Hold to Buy and raised his target price to $148 (from $116) following the release of …
